To Assess the Efficacy and Safety of Intravitreal Ranibiz... | NCT01846299

NCT01846299

ID	Type	Description	Link
2012-005418-20	EudraCT Number

Status Module

Sponsor/Collaborators Module

Oversight Module

Description Module

Conditions Module

Design Module

Interventional Study Design

Biospecimen

No data available

No data is available for this block.

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Ranibizumab	Experimental	A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.	Drug: Ranibizumab
Sham control	Sham Comparator	Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At month 1, if treatment was needed, sham was administered. At month 2, participants switched to open-label ranibizumab on an as needed basis.	Other: Sham control

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Sham control	Other	The sham vial did not contain active drug (empty sterile vial). The sham injection was an imitation of an intravitreal injection using an injection syringe without a needle touching the eye.

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Change From Baseline in Best-corrected Visual Acuity (BCVA) in Study Eye	BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. A positive change from baseline indicated improvement.	Baseline, Month 2

Secondary Outcomes

Measure	Description	Time Frame
Change From Baseline in BCVA in Study Eye up to Month 2	BCVA was assessed in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity (VA) testing charts at an initial testing distance of 4 meters. A positive change from baseline indicated improvement.	Baseline, Month 1, Month 2

Eligibility Module

Contacts/Locations Module

Name	Affiliation	Role
Novartis Pharmaceuticals	Novartis Pharmaceuticals	Study Director

Facility	Status	City	State	ZIP	Country	Contacts
Novartis Investigative Site		Sydney	New South Wales	2000	Australia
Novartis Investigative Site

References Module

No data available

No data is available for this block.

IPD Sharing Statement Module

No data available

No data is available for this block.

Results Section

Participant Flow Module

Arm/Group Information

ID	Title	Description
FG000	Ranibizumab	A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
FG001	Sham	Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At Month 1, if treatment was needed, sham was administered. At Month 2, participants could switch to open-label ranibizumab on an as needed basis.

Baseline Characteristics Module

Outcome Measures Module

Adverse Events Module

More Info Module

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Submission Tracking

No data available

No data is available for this block.

Condition Browse Module

Intervention Browse Module

Masking Info

Type of Units Analyzed

Arm/Group Information

ID	Title	Description
BG000	Ranibizumab	A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
BG001	Sham	Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At Month 1, if treatment was needed, sham was administered. At Month 2, participants could switch to open-label ranibizumab on an as needed basis.
BG002	Total	Total of all reporting groups

Baseline Measures

Title

Description

Population Description

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Denominator Units Selected

Denominators

Classes

Age, Continuous

Mean

Standard Deviation

Years

Title

Denominators

Categories

Title	Measurements
	OG0005.7± 0.81 OG0012.9± 0.89

Group IDs	Group Description	Statistical Method	Statistical Comment	P-Value	P-Value Comment	Parameter Type	Parameter Value	Dispersion Type	Dispersion Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	CI Lower Limit Comment	CI Upper Limit Comment	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type	Non-Inferiority Comment	Other Analysis Description
OG000 OG001		Mixed Models Analysis		0.0111		Mean Difference (Net)	2.78	Standard Error of the Mean	1.203	2-Sided	95	0.40	5.16				No	Superiority or Other

Secondary

Change From Baseline in BCVA in Study Eye up to Month 2

The full analysis set (FAS) was considered for the analysis. The FAS. The FAS included all randomized participants who received at least one dose of study treatment. Only participants of the FAS, who had data at baseline and the specific post-baseline time point, were included in the analysis for that time point.

Posted

Least Squares Mean

Standard Error

letters

Baseline, Month 1, Month 2

ID	Title	Description
OG000	Ranibizumab	A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
OG001	Sham With Ranibizumab	Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At Month 1, if treatment was needed, sham was administered. At Month 2, participants could switch to open-label ranibizumab on an as needed basis.

Units	Counts

Secondary

Change From Baseline in Central Subfield Thickness (CSFT) in Study Eye

CSFT wasassessed by optical coherence tomography (OCT). A negative change from baseline indicates improvement.

The full analysis set (FAS) was considered for the analysis. The FAS included all randomized participants who received at least one dose of study treatment. Only participants of the FAS, who had data at baseline and the specific post-baseline time point, were included in the analysis for that time point.

Posted

Mean

Standard Deviation

micrometers (um)

Baseline, Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12

ID	Title	Description
OG000	Ranibizumab	A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
OG001	Sham With Ranibizumab	Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At Month 1, if treatment was needed, sham was administered. At Month 2, participants could switch to open-label ranibizumab on an as needed basis.

Units	Counts
Participants

Secondary

Change From Baseline in Central Subfield Volume (CSFV) in Study Eye

CSFV was assessed OCT. A negative change from baseline indicates improvement.

Posted

Mean

Standard Deviation

microliters (ul)

Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12

ID	Title	Description
OG000	Ranibizumab	A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
OG001	Sham With Ranibizumab	Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At Month 1, if treatment was needed, sham was administered. At Month 2, participants could switch to open-label ranibizumab on an as needed basis.

Units	Counts
Participants

Secondary

Number of Participants With Presence or Absence of Intra-retinal Fluid in Study Eye Compared to Baseline

The presence of intra-retinal fluid was assessed by OCT.

The FAS was considered for the analysis. The FAS included all randomized participants who received at least one dose of study treatment. Only participants (n), with values 'Absent' or 'Definite' for both the baseline and corresponding post-baseline time point, were included in the analysis.

Posted

Number

Participants

Month 2, Month 6, Month 12

ID	Title	Description
OG000	Ranibizumab	A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
OG001	Sham With Ranibizumab	Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At Month 1, if treatment was needed, sham was administered. At Month 2, participants could switch to open-label ranibizumab on an as needed basis.

Units	Counts
Participants

Secondary

Number of Participants With Presence or Absence of Subretinal Fluid in Study Eye Compared to Baseline

The presence of subretinal fluid was assessed by OCT.

Posted

Number

Participants

Month 2, Month 6, Month 12

ID	Title	Description
OG000	Ranibizumab	A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
OG001	Sham With Ranibizumab	Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At Month 1, if treatment was needed, sham was administered. At Month 2, participants could switch to open-label ranibizumab on an as needed basis.

Units	Counts
Participants

Secondary

Number of Participants With Presence of Active Macular Edema (ME) Leakage

The presence of active ME leakage was assessed by fluorescein angiography (FA).

The FAS was used this analysis. The FAS included randomized participants who received at least one dose of study treatment.

Posted

Number

Participants

Month 2

ID	Title	Description
OG000	Ranibizumab	A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
OG001	Sham With Ranibizumab	Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At Month 1, if treatment was needed, sham was administered. At Month 2, participants could switch to open-label ranibizumab on an as needed basis.

Units	Counts
Participants	OG000

Secondary

Number of Participants Requiring Rescue Treatment at Month 1

Rescue treatment with laser photocoagulation or periocular treatment could be administered at Month 1 only if the participant had a visual acuity loss of > 5 letters due to disease activity from baseline to Month 1.

The FAS was used for this analysis. The FAS included all randomized participants who received at least one dose of study treatment.

Posted

Number

Participants

Month 1

ID	Title	Description
OG000	Ranibizumab	A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
OG001	Sham With Ranibizumab	Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At Month 1, if treatment was needed, sham was administered. At Month 2, participants could switch to open-label ranibizumab on an as needed basis.

Units	Counts
Participants

Secondary

Average Change From Baseline in BCVA

The FAS was used for this analysis. The FAS included randomized participants who received at least one dose of study medication.

Posted

Mean

Standard Deviation

letters

Baseline (BL), month 1 through month 6, month 1 through month 12

ID	Title	Description
OG000	Ranibizumab	A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
OG001	Sham With Ranibizumab	Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At Month 1, if treatment was needed, sham was administered. At Month 2, participants could switch to open-label ranibizumab on an as needed basis.

Units	Counts
Participants

Secondary

Number of Participants With ≥ 1, ≥ 5, ≥ 10 and ≥ 15 Letters Gain or Reaching 84 Letters

VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using ETDRS-like visual acuity testing charts at a testing distance of 4 meters.

Posted

Number

Participants

Month 2, Month 6 , Month 12

ID	Title	Description
OG000	Ranibizumab	A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
OG001	Sham With Ranibizumab	Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At Month 1, if treatment was needed, sham was administered. At Month 2, participants could switch to open-label ranibizumab on an as needed basis.

Units	Counts

Secondary

Number of Participants With > 1, > 5, > 10 and > 15 Letters Loss

VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using ETDRS-like visual acuity testing charts at a testing distance of 4 meters.

Posted

Number

Participants

Month 2, Month 6, Month 12

ID	Title	Description
OG000	Ranibizumab	A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
OG001	Sham With Ranibizumab	Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At Month 1, if treatment was needed, sham was administered. At Month 2, participants could switch to open-label ranibizumab on an as needed basis.

Units	Counts

Secondary

Number of Participants With Ranibizumab Treatments

The number of participants administered study treatments, according to treatment frequency, was assessed.

The safety set was used for this analysis. The safety set included randomized participants who received at least one dose of study treatment. Two participants from the sham group were included in the ranibizumab group based on the actual treatment received.

Posted

Number

Participants

Month 12

ID	Title	Description
OG000	Ranibizumab	A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
OG001	Sham With Ranibizumab	Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At Month 1, if treatment was needed, sham was administered. At Month 2, participants could switch to open-label ranibizumab on an as needed basis.
OG002	Sham Without Ranibizumab	Participants did not receive ranibizumab at any time during the study.

Secondary

Number of Participants With Re-treatments

The number of participants, administered re-treatments according to treatment frequency, was assessed. Re-treatment was defined as an administration of study medication following at least one non-missed visit where treatment was not administered in the study eye. Up to Month 12, the maximum number of retreatments was 5.

Posted

Number

Participants

Month 6, month 12

ID	Title	Description
OG000	Ranibizumab	A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
OG001	Sham With Ranibizumab	Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At Month 1, if treatment was needed, sham was administered. At Month 2, participants could switch to open-label ranibizumab on an as needed basis.
OG002	Sham Without Ranibizumab	Participants did not receive ranibizumab at any time during the study.

Secondary

Number of Primary Reasons for Decision to Treat by Investigator

The total number of primary reasons for decisions to treat was assessed. A single participant could have had multiple primary reasons for treatment.

Posted

Number

Number of primary reasons

12 months

Reasons

Participants

ID	Title	Description
OG000	Ranibizumab	A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
OG001	Sham With Ranibizumab	Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At Month 1, if treatment was needed, sham was administered. At Month 2, participants could switch to open-label ranibizumab on an as needed basis.
OG002	Sham Without Ranibizumab	Participants did not receive ranibizumab at any time during the study.

Arm/Groups

ID	Title	Description	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Ranibizumab 0.5mg	Ranibizumab 0.5mg	15	119	58	119
EG001	Sham With Ranibizumab 0.5mg	Sham with Ranibizumab 0.5mg	6	56	21	56
EG002	Sham Without Ranibizumab 0.5mg	Sham without Ranibizumab 0.5mg	1	2	0	2

Serious Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Atrial fibrillation	Cardiac disorders	MedDRA 18.0	Systematic Assessment	EG0001 affected119 at risk EG0010 affected56 at risk EG0020 affected2 at risk
Cardio-respiratory arrest	Cardiac disorders	MedDRA 18.0	Systematic Assessment	EG0000 affected119 at risk EG0011 affected56 at risk EG0020 affected2 at risk
Conjunctivitis allergic (Fellow treated eye)	Eye disorders	MedDRA 18.0	Systematic Assessment	EG0001 affected119 at risk EG0010 affected56 at risk EG0020 affected2 at risk
Conjunctivitis allergic (Study eye)	Eye disorders	MedDRA 18.0	Systematic Assessment	EG0001 affected119 at risk EG0010 affected56 at risk EG0020 affected2 at risk
Corneal oedema (Fellow treated eye)	Eye disorders	MedDRA 18.0	Systematic Assessment	EG0000 affected119 at risk EG0011 affected56 at risk EG0020 affected2 at risk
Open angle glaucoma (Fellow untreated eye)	Eye disorders	MedDRA 18.0	Systematic Assessment	EG0001 affected119 at risk EG0010 affected56 at risk EG0020 affected2 at risk
Open angle glaucoma (Study eye)	Eye disorders	MedDRA 18.0	Systematic Assessment	EG0001 affected119 at risk EG0010 affected56 at risk EG0020 affected2 at risk
Gastritis	Gastrointestinal disorders	MedDRA 18.0	Systematic Assessment	EG0000 affected119 at risk EG0011 affected56 at risk EG0020 affected2 at risk
Intestinal obstruction	Gastrointestinal disorders	MedDRA 18.0	Systematic Assessment	EG0001 affected119 at risk EG0010 affected56 at risk EG0020 affected2 at risk
Pancreatitis acute	Gastrointestinal disorders	MedDRA 18.0	Systematic Assessment	EG0000 affected119 at risk EG0011 affected56 at risk EG0020 affected2 at risk
Hypothermia	General disorders	MedDRA 18.0	Systematic Assessment	EG0001 affected119 at risk EG0010 affected56 at risk EG0020 affected2 at risk
Biliary colic	Hepatobiliary disorders	MedDRA 18.0	Systematic Assessment	EG0001 affected119 at risk EG0010 affected56 at risk EG0020 affected2 at risk
Anaphylactic reaction	Immune system disorders	MedDRA 18.0	Systematic Assessment	EG0001 affected119 at risk EG0010 affected56 at risk EG0020 affected2 at risk
Endophthalmitis (Study eye)	Infections and infestations	MedDRA 18.0	Systematic Assessment	EG0001 affected119 at risk EG0010 affected56 at risk EG0020 affected2 at risk
Herpes zoster cutaneous disseminated	Infections and infestations	MedDRA 18.0	Systematic Assessment	EG0001 affected119 at risk EG0010 affected56 at risk EG0020 affected2 at risk
Pneumonia	Infections and infestations	MedDRA 18.0	Systematic Assessment	EG0001 affected119 at risk EG0010 affected56 at risk EG0020 affected2 at risk
Shunt stenosis	Injury, poisoning and procedural complications	MedDRA 18.0	Systematic Assessment	EG0001 affected119 at risk EG0010 affected56 at risk EG0020 affected2 at risk
Prostatic specific antigen increased	Investigations	MedDRA 18.0	Systematic Assessment	EG0001 affected119 at risk EG0010 affected56 at risk EG0020 affected2 at risk
Hypokalaemia	Metabolism and nutrition disorders	MedDRA 18.0	Systematic Assessment	EG0000 affected119 at risk EG0011 affected56 at risk EG0020 affected2 at risk
Mobility decreased	Musculoskeletal and connective tissue disorders	MedDRA 18.0	Systematic Assessment	EG0000 affected119 at risk EG0011 affected56 at risk EG0020 affected2 at risk
Muscular weakness	Musculoskeletal and connective tissue disorders	MedDRA 18.0	Systematic Assessment	EG0000 affected119 at risk EG0011 affected56 at risk EG0020 affected2 at risk
Hepatocellular carcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	MedDRA 18.0	Systematic Assessment	EG0000 affected119 at risk EG0011 affected56 at risk EG0020 affected2 at risk
Malignant melanoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	MedDRA 18.0	Systematic Assessment	EG0000 affected119 at risk EG0011 affected56 at risk EG0020 affected2 at risk
Meningioma benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	MedDRA 18.0	Systematic Assessment	EG0000 affected119 at risk EG0011 affected56 at risk EG0020 affected2 at risk
Basilar artery thrombosis	Nervous system disorders	MedDRA 18.0	Systematic Assessment	EG0000 affected119 at risk EG0010 affected56 at risk EG0021 affected2 at risk
Brain stem stroke	Nervous system disorders	MedDRA 18.0	Systematic Assessment	EG0000 affected119 at risk EG0010 affected56 at risk EG0021 affected2 at risk
Cerebral haemorrhage	Nervous system disorders	MedDRA 18.0	Systematic Assessment	EG0001 affected119 at risk EG0010 affected56 at risk EG0020 affected2 at risk
Dizziness	Nervous system disorders	MedDRA 18.0	Systematic Assessment	EG0001 affected119 at risk EG0010 affected56 at risk EG0020 affected2 at risk
Presyncope	Nervous system disorders	MedDRA 18.0	Systematic Assessment	EG0001 affected119 at risk EG0010 affected56 at risk EG0020 affected2 at risk
Transient ischaemic attack	Nervous system disorders	MedDRA 18.0	Systematic Assessment	EG0001 affected119 at risk EG0010 affected56 at risk EG0020 affected2 at risk
Dysuria	Renal and urinary disorders	MedDRA 18.0	Systematic Assessment	EG0000 affected119 at risk EG0011 affected56 at risk EG0020 affected2 at risk
Nephrolithiasis	Renal and urinary disorders	MedDRA 18.0	Systematic Assessment	EG0001 affected119 at risk EG0010 affected56 at risk EG0020 affected2 at risk
Urinary tract obstruction	Renal and urinary disorders	MedDRA 18.0	Systematic Assessment	EG0001 affected119 at risk EG0010 affected56 at risk EG0020 affected2 at risk
Benign prostatic hyperplasia	Reproductive system and breast disorders	MedDRA 18.0	Systematic Assessment	EG0001 affected119 at risk EG0010 affected56 at risk EG0020 affected2 at risk
Atelectasis	Respiratory, thoracic and mediastinal disorders	MedDRA 18.0	Systematic Assessment	EG0001 affected119 at risk EG0010 affected56 at risk EG0020 affected2 at risk
Chronic obstructive pulmonary disease	Respiratory, thoracic and mediastinal disorders	MedDRA 18.0	Systematic Assessment	EG0002 affected119 at risk EG0010 affected56 at risk EG0020 affected2 at risk
Dermatitis allergic	Skin and subcutaneous tissue disorders	MedDRA 18.0	Systematic Assessment	EG0001 affected119 at risk EG0010 affected56 at risk EG0020 affected2 at risk
Aortic stenosis	Vascular disorders	MedDRA 18.0	Systematic Assessment	EG0001 affected119 at risk EG0010 affected56 at risk EG0020 affected2 at risk

Other Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Conjunctival haemorrhage (Study eye)	Eye disorders	MedDRA 18.0	Systematic Assessment	EG00011 affected119 at risk EG0017 affected56 at risk EG0020 affected2 at risk
Cystoid macular oedema (Study eye)	Eye disorders	MedDRA 18.0	Systematic Assessment	EG0006 affected119 at risk EG0010 affected56 at risk EG0020 affected2 at risk
Dry eye (Study eye)	Eye disorders	MedDRA 18.0	Systematic Assessment	EG0006 affected119 at risk EG0011 affected56 at risk EG0020 affected2 at risk
Eye pain (Study eye)	Eye disorders	MedDRA 18.0	Systematic Assessment	EG00010 affected119 at risk EG0012 affected56 at risk EG0020 affected2 at risk
Macular oedema (Fellow untreated eye)	Eye disorders	MedDRA 18.0	Systematic Assessment	EG0001 affected119 at risk EG0013 affected56 at risk EG0020 affected2 at risk
Macular oedema (Study eye)	Eye disorders	MedDRA 18.0	Systematic Assessment	EG0007 affected119 at risk EG0012 affected56 at risk EG0020 affected2 at risk
Visual acuity reduced (Study eye)	Eye disorders	MedDRA 18.0	Systematic Assessment	EG00011 affected119 at risk EG0013 affected56 at risk EG0020 affected2 at risk
Influenza	Infections and infestations	MedDRA 18.0	Systematic Assessment	EG0006 affected119 at risk EG0013 affected56 at risk EG0020 affected2 at risk
Nasopharyngitis	Infections and infestations	MedDRA 18.0	Systematic Assessment	EG00012 affected119 at risk EG0012 affected56 at risk EG0020 affected2 at risk
Intraocular pressure increased (Study eye)	Investigations	MedDRA 18.0	Systematic Assessment	EG0006 affected119 at risk EG0013 affected56 at risk EG0020 affected2 at risk
Hypertension	Vascular disorders	MedDRA 18.0	Systematic Assessment	EG0006 affected119 at risk EG0012 affected56 at risk EG0020 affected2 at risk

ID	Term
D008269	Macular Edema
D014786	Vision Disorders

Ancestor Terms

ID	Term
D008268	Macular Degeneration
D012162	Retinal Degeneration
D012164	Retinal Diseases
D005128	Eye Diseases
D012678	Sensation Disorders
D009461	Neurologic Manifestations
D009422	Nervous System Diseases
D012816	Signs and Symptoms
D013568	Pathological Conditions, Signs and Symptoms

ID	Term
D000069579	Ranibizumab

Ancestor Terms

ID	Term
D061067	Antibodies, Monoclonal, Humanized
D000911	Antibodies, Monoclonal
D000906	Antibodies
D007136	Immunoglobulins
D007162	Immunoproteins
D001798	Blood Proteins
D011506	Proteins
D000602	Amino Acids, Peptides, and Proteins
D012712	Serum Globulins
D005916	Globulins

Units	Counts
Participants	OG000119 OG00156 OG0022